Seasonal Variability of Severe Asthma Exacerbations and Clinical Benefit from Lebrikizumab

Short Summary Post-hoc analyses of two Phase III studies of lebrikizumab in moderate to severe asthma suggest that IL-13 inhibition is effective at preventing seasonal exacerbations in subjects with high blood eosinophil counts. Further work is required to understand and treat exacerbations that are...

Full description

Saved in:
Bibliographic Details
Published inJournal of allergy and clinical immunology Vol. 139; no. 5; pp. 1682 - 1684.e3
Main Authors Staton, Tracy L., PhD, Arron, Joseph R., MD, PhD, Olsson, Julie, MD, MS, Holweg, Cécile TJ., PhD, Matthews, John G., MB, BS, PhD, Choy, David F., BS
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.05.2017
Elsevier Limited
Subjects
Allergens
Allergies
Allergy and Immunology
Annual variations
Asthma
Atopy
Children
Cytokines
Degranulation
Environmental factors
Eosinophils
Epidemiology
Hypersensitivity
Immune response
Immunoglobulin E
Infections
Inflammation
Interleukin 4
Leukocytes (basophilic)
Leukocytes (eosinophilic)
Mast cells
Precipitates
Respiration
Respiratory tract
Respiratory tract diseases
Rhinovirus
Seasons
Studies
Thymic stromal lymphopoietin
Viral infections
RR
RV
IgE
Interleukin-13
asthma
IL-13
rhinovirus
seasonal exacerbations
rate reduction
Immunoglubulin E
Type 2
ICS
Inhaled Corticosteroids
TH2
Online AccessGet full text

Cover

More Information
Summary:Short Summary Post-hoc analyses of two Phase III studies of lebrikizumab in moderate to severe asthma suggest that IL-13 inhibition is effective at preventing seasonal exacerbations in subjects with high blood eosinophil counts. Further work is required to understand and treat exacerbations that are independent of seasonal and Type 2 pathway factors.
Bibliography:SourceType-Other Sources-1
ObjectType-Correspondence-1
ObjectType-News-2
content type line 66
ObjectType-Article-3
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2017.01.028